23948sdkhjf
  • {{ window.visitor.corporateClient.name }}
    Corporate solution
    {{ window.visitor.ipAccess.corporateClient.name }}
    {{ window.visitor.corporateClient.name }}

  • Welcome to our Corporate client solution

    Here you can administrate your corporate solutions users.

  • Welcome to your subscription for Life Science Nordic

  • Welcome to our Corporate client solution

    Your IP is registered with the company mentioned above and provides access to Life Science Nordic.

  • Click here to go to sign-up
Log in or create to bookmark articles
Get access to all content on Life Science Nordic
No commitment or card information required
Try Life Science Nordic now
Applies to personal subscription only.
Contact us for a enterprise solution.
Advertisement
Advertisement

LEO Pharma acquires dermatology drug for 435 million USD

LEO Pharma strengthens its dermatology portfolio by acquiring the late-stage drug candidate dersimelagon.
Advertisement

Danish pharmaceutical company LEO Pharma has made an acquisition of the worldwide rights to dersimelagon from Japanese corporation Tanabe Pharma.

Dersimelagon is an investigational orally-ingested drug for the rare genetic skin diseases EPP and XLP.

LEO Pharma will pay 435 million USD for the rights, the Danish dermatology specialist announces in a press release.

Advertisement Advertisement
BREAKING
{{ article.headline }}
0.125|